This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
DIM
Bio-active dimer of indole-3-carbinol (the cruciferous-vegetable phytochemical), sold OTC as an "estrogen balancer." Mechanism is real but mismarketed: DIM is not an aromatase inhibitor — it induce…
Aliases (4)
Overview
What is DIM?
Bio-active dimer of indole-3-carbinol (the cruciferous-vegetable phytochemical), sold OTC as an "estrogen balancer." Mechanism is real but mismarketed: DIM is not an aromatase inhibitor — it induces hepatic CYP1A1/1A2 and shifts estradiol hydroxylation from 16α-OH (proliferative) toward 2-OH (weakly estrogenic), without consistently changing total estrogen levels. Clinically meaningful in narrow populations: peri/postmenopausal women on HRT, PCOS-driven hyperandrogenism, fibrocystic breast disease, AAS users managing aromatized estradiol. At doses ≥200 mg/day chronic, DIM is AR-antagonistic in human prostate tissue and reduces testosterone in rodent models — the opposite of what "natural T-booster" marketing claims. For Dylan (20yo lean MMA athlete, no estrogen issue, no AAS, normal HPG axis): SKIP. No upside, real downside risk to androgen tone in the exact archetype that doesn't need it. Better cruciferous lever for NRF2/phase II support is sulforaphane.
Pharmacokinetics
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
Strong pharmacological complementarity. CDG inhibits β-glucuronidase, preventing reabsorption of glucuronidated estrogens in the gut — so phase II conjugatio…
Both cruciferous-derived but mechanistically distinct (sulforaphane = NRF2 activator → phase II detox enzymes; DIM = AhR → CYP1A induction). Some practitione…
Estrogen detoxification requires methylation (COMT methylates 2-OH-E1 to 2-methoxy-E1, the cleanest exit). Methyl-donor support reduces "estrogen detox stall."
Standard hormonal-balance adjuncts; no specific DIM synergy beyond background nutrition.
DIM is not an AI but stacking with prescription AIs risks over-suppression of estradiol in AAS users. Pick one lever, dial in, then add if needed — don't bla…
Thomson 2017 RCT showed DIM reduces active tamoxifen metabolite (endoxifen) levels via CYP induction. Avoid in tamoxifen patients without oncologist sign-off.
taken at therapeutic dose (theophylline, clozapine, olanzapine, tizanidine): CYP1A2 induction by DIM accelerates clearance and may drop these drugs sub-thera…
Theoretical reduced efficacy. If on the pill / patch / ring, layer barrier or non-hormonal IUD when starting DIM.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety 7
Side Effects
- 1Dark/orange urine — harmless DIM metabolite excretion, often mistaken for dehydration or liver concern.
- 2Headache, especially first 1-2 weeks.
- 3Mild GI (nausea, soft stool) if taken on empty stomach.
- 4Reduced libido / erection quality — strongly dose-dependent, more common at 200+ mg/day chronic in men.
- 5"Flat" mood, mild fatigue (consistent with reduced androgen tone or altered estrogen signaling).
- 6Hormonal acne flare (paradoxical, in subset of users — likely transient as 2-OH:16α ratio shifts).
- 7Menstrual cycle changes in women (lengthening or shortening, transient).
When to Stop
- Hyponatremia at very high doses (≥600 mg/day): case-reported; mechanism unclear, possibly AhR-mediated water/sodium handling effects. Worth knowing if a user is stacking DIM with diuretics or has CHF.
- Anti-androgenic syndrome (multi-month chronic high dose): clinical low-T picture without underlying HPG pathology — fatigue, reduced libido, mood drop. Resolves on discontinuation in case reports, but the duration of recovery is undercharacterized.
- Reduced contraceptive efficacy: plausible via CYP1A2 induction increasing clearance of ethinyl estradiol and some progestins; no formal PK study quantifying magnitude. Treat as theoretical-but-real until disproven.
- Theoretical fetal/lactation harm: modulates estrogen metabolism in a context where physiological estrogen elevation matters. Contraindicated in pregnancy and breastfeeding.
- Weeks 1-2: headache, GI, orange urine — usually transient.
- Weeks 4-8: libido/erection check in men.
- Months 2-3: AAS users — repeat E2 sensitive assay to confirm desired shift, avoid over-suppression.
- Months 3-6: women on cyclic regimens — track cycle regularity, mood, breast tenderness.
References
Reed et al. 2008 — phase I pharmacokinetics + tolerability of BR-DIM in healthy women (PMID 18843002)
foundational dose-tolerability + PK study.
View StudyCastañon et al. 2012 — DIM 150 mg/day × 6 mo in cervical cytological abnormalities, n=551 RCT (PMID 22075942)
well-tolerated, no clinical benefit on cytology/HPV.
View StudyThomson et al. 2017 — BR-DIM 150 mg BID × 12 mo in tamoxifen-treated breast cancer survivors RCT (PMID 28560655)
raised 2:16 ratio, increased SHBG, reduced active tamoxifen metabolites.
View StudyHeath et al. 2016 — anti-androgenic activity of BR-DIM in prostatectomy patients (PMID 27069550)
96% AR nuclear exclusion, 71% PSA decline; direct demonstration of anti-androgenic biology in human tissue.
View StudyRajoria et al. 2011 — DIM modulates estrogen metabolism in thyroid proliferative disease (PMID 21254914)
tissue penetrance + 2:16 ratio shift at 300 mg/day × 14 days.
View StudyAksu et al. 2016 — DIM testicular toxicity + AR/ER modulation in male rats (PMID 26926141)
mechanistic basis for anti-androgenic risk at high doses.
View StudyPostmenopausal HRT RCT 2025 — DIM modulates estrogen metabolism in transdermal estradiol users (PMID 40298801)
confirms metabolism redirection without total-E2 reduction.
View StudyHwang et al. 2015 — phase IIa CIN multi-center DIM RCT (PMC4685602)
safety + biomarker shift in CIN.
View StudyReyes-Hernández et al. 2023 — I3C/DIM mechanisms in cancer chemoprevention (Cancer Cell International review)
comprehensive 2023 review of AhR / ER / NF-kB / apoptosis pathways.
View StudyThomson et al. 2016 — chemopreventive properties of DIM in breast cancer review (PMID 27261275)
review of experimental + human evidence.
View StudyAnti-Cancer and Other Biological Effects of DIM — systematic review of human clinical trials (Dove Press 2020)
comprehensive human-trial synthesis.
View StudyDIM activates PXR → CYP3A4 + MDR1 induction (PMC4568078)
mechanistic basis for non-CYP1A drug interactions.
View StudyMemorial Sloan Kettering — Diindolylmethane integrative medicine monograph
clinical reference for oncology context.
View StudyPlant-derived 3,3'-DIM is a strong AR antagonist (PMID 12665522)
foundational paper on AR antagonism mechanism.
View StudyDIM-mediated AhR antiestrogenic activity (PMID 9771935)
foundational AhR mechanism paper.
View StudyLatest research
- rctImpact of 3,3'-diindolylmethane on estradiol and estrogen metabolism in postmenopausal women using a transdermal estradiol patchBR-DIM 150 mg BID for 4 weeks shifted urinary 2-OH:16α-OH ratio in postmenopausal HRT users without altering total estradiol exposure.
- review3,3'-Diindolylmethane and indole-3-carbinol — therapeutic molecules for cancer chemoprevention via cellular signaling pathwaysComprehensive 2023 review of I3C/DIM mechanisms — AhR ligand, ER modulation, NF-kB, apoptosis pathways across breast/prostate/cervical/colon contexts.
- rctDiindolylmethane for breast cancer biomarker modulation in tamoxifen patients — RCTBR-DIM 150 mg BID × 12 months raised 2:16α-OHE1 ratio and SHBG; reduced active tamoxifen metabolites (endoxifen) — clinically meaningful interaction.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.